Get the Stockscreener App
33.07
0.09%
-0.03
After Hours:
32.83
-0.24
-0.73%
Harrow Inc stock is traded at $33.07, with a volume of 372.04K.
It is down -0.09% in the last 24 hours and down -19.99% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
See More
Previous Close:
$33.10
Open:
$33
24h Volume:
372.04K
Relative Volume:
0.63
Market Cap:
$1.24B
Revenue:
$272.30M
Net Income/Loss:
$-5.14M
P/E Ratio:
-202.26
EPS:
-0.1635
Net Cash Flow:
$42.76M
1W Performance:
-0.03%
1M Performance:
-19.99%
6M Performance:
-9.02%
1Y Performance:
-28.34%
1-Day Range:
$32.58
$33.28
1-Week Range:
$32.50
$34.87
52-Week Range:
$28.54
$54.85
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, TEVA, HLN, ZTS, VTRS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
33.07 | 1.24B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
Insider Confidence In These Growth Stocks For September 2026 - simplywall.st
Harrow Health stock falls 1.55 percent despite Q2 growth - AD HOC NEWS
HROW6348836 Bond Profile: Coupon and Redemption - TradingView
Harrow (HROW) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Harrow, Inc. (HROW) Stock Analysis: Unveiling a 91.63% Potential Upside in the Eyecare Pharmaceutical Sector - DirectorsTalk Interviews
Harrow, Inc. stock gains as market cap nears USD 1.2 billion - AD HOC NEWS
Harrow Health stock holds steady as investors digest recent growth figures - AD HOC NEWS
Harrow Inc. stock dips after valuation signal highlights potential upside - AD HOC NEWS
Is Harrow Inc (HROW) a Bargain After 3.2% Drop? GF Value Says Un - GuruFocus
Is Harrow Inc (HROW) a Bargain After 5.7% Drop? GF Value Says Un - GuruFocus
Harrow at Cantor healthcare conference: long view, bigger eye-care bet - investing.com
HROW Initiates Coverage On Harrow -- Outperform Rating by Leerin - GuruFocus
Andrew R. Boll Assumes Principal Accounting Officer Role at Harrow (NASDAQ: HROW) - Kalkine Media
Harrow Inc. (HROW) Slides 2.96% to $37.4, Approaches Support at $35.53Swing Entry Signals - siam.in
Andrew R. Boll named Harrow principal accounting officer as Randall E. Pollard departs - TradingView
Harrow, Inc. Announces Management Changes, Effective September 4, 2026 - marketscreener.com
Harrow Health Inc. (HROW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Harrow Health Inc. 8.625% Senior Notes due 2026 (HROWL) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
HROW Q2 2026 Earnings: EPS Misses Estimates as Losses DeepenMid-Term Outlook - vinanet.vn
Harrow Health Inc. 8.625% Senior Notes due 2026 (HROWL) Key Financial Ratios – Valuation, Profitability & More - Value Research
Harrow Inc stock gains as analysts see strong revenue growth ahead - ad-hoc-news.de
Harrow Inc (HROW) Stock Up 5.6% and Still Undervalued -- GF Scor - GuruFocus
Harrow Health Inc. 8.625% Senior Notes due 2026 (HROWL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Harrow to Participate in Three Investor Conferences in September - GlobeNewswire
Harrow Health Inc. 8.625% Senior Notes due 2026 (HROWL) Peer Comparison – Compare with Others - Value Research
Harrow (HROW) Reported Positive IHEEZO Study Results In Intravitreal Injections - Sahm
Harrow (HROW) Quarterly Results: EPS Falls Short of Its Estimate in the Current Update; Price Move - vinanet.vn
HROW | Harrow, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half - Sahm
Harrow (NASDAQ: HROW) CSO sells 11,250 shares in August option trade - Stock Titan
Harrow (HROW) Outlook: Ends Down by 2.64% at $40.95 for the Current Session; Next Session: Price Remains Between $38.90 Support and $43.00 Resistance on the DayShort Term Trading Ideas - vinanet.vn
What's Going On With Harrow Stock Friday?Harrow (NASDAQ:HROW) - Benzinga
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections - Sahm
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target - Yahoo Finance
In a 50-patient study, Harrow’s eye gel was linked to about 58% less injection discomfort - Stock Titan
Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In? - simplywall.st
Harrow And 2 Other Growth Stocks Insiders Are Betting On - simplywall.st
Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com South Africa
Harrow CSO Amir Shojaei sells $450,000 in company stock - Investing.com
Rice Hall James & Associates LLC Takes Position in Harrow, Inc. $HROW - MarketBeat
Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy? - simplywall.st
Harrow (HROW) Q2 2026 Earnings Call Transcript - The Globe and Mail
Harrow (NASDAQ:HROW) Insider Amir Shojaei Sells 11,250 Shares - MarketBeat
Harrow Inc. (HROW) Slips 1.79% as Shares Test Key Support ZoneLast Point Resistance - vinanet.vn
HROW Q2 2026 Earnings: Wider Loss of $0.34 per Share Misses Estimates by 85.19%, but Stock Rises 2.98 - vinanet.vn
Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold" - MarketBeat
HC Wainwright Issues Pessimistic Outlook for Harrow Earnings - marketbeat.com
Royce Micro-Cap Fund's Harrow Inc(HROW) Holding History - GuruFocus
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance
Harrow: The Q2 Turnaround Is Enough For A Cautious Buy (NASDAQ:HROW) - Seeking Alpha
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):